You are here

DIAGNOSTIC TEST FOR CHRONIC FATIGUE AND FIBROMYALGIA

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: AR44455-01
Agency Tracking Number: 39245
Amount: $65,690.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
144 ELKS PLACE, STE 1402
New Orleans, LA 70112
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 WILSON, RUSSELL B
 () -
Business Contact
Phone: (504) 529-9944
Research Institution
N/A
Abstract

The long-term goal is to demonstrate that the Anti-Polymer Antibody Assay is diagnostic for chronic fatigue syndrome patients and fibromyalgia patients. In a pilot study 55 % (6/11) of chronic fatigue syndrome patient sera, 71 % (12/17) of fibromyalgia patient sera and 9 % (1/11) sera from healthy normals were seroreactive on the Anti-Polymer Antibody Assay. Therefore, it is hypothesized that the Anti-Polymer Antibody Assay is diagnostic for chronic fatigue syndrome patients and fibromyalgia patients. The purpose of this proposal is to establish the ability of the assay to identify chronic fatigue patient sera and fibromyalgia patient sera in a retrospective multi-center blinded trial. The data generated from the multi-center trial will be used as the basis for the submission of a prospective Phase II multicenter trial. In addition, data from the Phase I trial will be used in the application to the Food and Drug Administration for approval of the Anti-Polymer Antibody Assay as a diagnostic test for chronic fatigue syndrome and fibromyalgia.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government